Supreme Court’s Copaxone Ruling Could Increase Expert Witness Testimony
This article was originally published in The Pink Sheet Daily
High court rules Federal Circuit should have granted deference to district court’s decision on meaning of Copaxone patent claim; Federal Circuit must now reconsider its finding that the patent is invalid.
You may also be interested in...
Supreme Court asks the Solicitor General to weigh in on whether a state tort claim that Teva did not immediately update its generic Fosamax labeling is preempted by federal law; thousands of such suits have arisen in wake of high court’s Mensing decision.
Sandoz, which has first to file on the generic, may have the most to lose after federal judge finds that Mylan and Sandoz ANDAs for generic Copaxone infringe all the claims in Teva’s patents, the latest of which expires in September 2015. FDA now has more time to review the ANDAs without pressure.
Sanofi seeks to delay decision clearing path for Mylan's Lantus biosimilar; says it should be able to get rehearing based on Federal Circuit's ruling that PTAB judges were not constitutionally appointed.